Korro Bio, Inc. (KRRO) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$8.68

From 52W high−80.78%

Volume134852.00

Market cap$131.21M

P/E (TTM)—

P/S (TTM)55.1x

Div yield—

Key dataOct 19, 2026

Open

$8.68

From 52W high

−80.78%

Volume

134852.00

Market cap

$131.21M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.8x

P/E (TTM)

—

RSI (14)

34.6

MomentumView details →

1D Return

+4.95%

YTD Return

+6.87%

SummaryUpdated Jun 1, 2026

Korro Bio, Inc. (NASDAQ:KRRO) is a biopharmaceutical company founded in 2018 and headquartered in Cambridge, Massachusetts. The company went public in October 2019 and specializes in developing genetic medicines through RNA editing technology. Korro Bio focuses on creating treatments for both rare genetic diseases and more common conditions by correcting disease-causing mutations at the RNA level rather than permanently altering DNA. The company is currently in the clinical development stage with multiple programs targeting various therapeutic areas.

Ask drillr about Korro Bio, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.8x

EV/Sales

24.5x

P/S (TTM)

55.1x

P/B (TTM)

1.3x

ProfitabilityView details →

Gross Margin

72.75%

Net Margin

−4477.08%

EBITDA Margin

−3019.27%

ROE (TTM)

−103.31%

ROA (TTM)

−65.25%

Asset Turnover

0.01x

GrowthView details →

Revenue YoY

−62.08%

EPS YoY

−2.67%

FCF YoY

+7.57%

Revenue CAGR 3Y

+181.46%

EPS CAGR 3Y

−33.19%

EBITDA YoY

+23.48%

MomentumView details →

1D Return

+4.95%

YTD Return

+6.87%

1Y Return

−81.53%

RSI (14)

34.6

vs 50D SMA

−26.12%

vs 200D SMA

−27.26%

Capital & dividendView details →

Debt/Equity

0.41x

Current Ratio

9.55x

Quick Ratio

9.55x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.07

EPS Surprise

20.15%

Beats (12Q)

6/12

Next Q EPS Est

−$1.35

Avg Surprise (4Q)

−29.00%

Rev Surprise

600.00%

Financials snapshotView financials →

Revenue (TTM)

2.38M

Net Income (TTM)

−106.64M

Op. CF (TTM)

−67.95M

Next earningsNov 11, 2026 →

Latest newsMore news →

Korro Bio, Inc. exchanged 1,000,000 outstanding common shares for pre-funded warrants to purchase 1,000,000 new shares of common stock, with an exercise price of $0.001 per share, in a transaction with Venrock Healthcare Capital Partners entities on August 6, 2026.75d ago

Similar companies

Avidity Biosciences, Inc.RNA Tiziana Life Sciences LtdTLSA Acumen Pharmaceuticals, Inc.ABOS Tharimmune, Inc.CNTN AN2 Therapeutics, Inc.ANTX Voyager Therapeutics, Inc.VYGR Find similar companies →

Latest newsMore news →

Korro Bio dosed the first cohort of participants in its Phase 1/2 ANCHOR clinical trial of KRRO-121, a GalNAc-conjugated RNA-editing oligonucleotide for hyperammonemia in urea cycle disorders and hepatic encephalopathy.14d ago Korro Bio, Inc. exchanged 1,000,000 outstanding common shares for pre-funded warrants to purchase 1,000,000 new shares of common stock, with an exercise price of $0.001 per share, in a transaction with Venrock Healthcare Capital Partners entities on August 6, 2026.75d ago